Tango Therapeutics (TNGX) Investor presentation summary

PRMT5 inhibitor franchise and clinical development

• Advancing vopimetostat and TNG456, selective PRMT5 inhibitors, for MTAP-deleted cancers, with vopimetostat showing first- and best-in-class potential and TNG456 targeting CNS tumors like glioblastoma.

• Vopimetostat demonstrated robust monotherapy activity (27% ORR across 16 histologies, 49% ORR in histology-selective cohort) and favorable safety profile, with no discontinuations at 250 mg QD.

• Combination of vopimetostat with RAS (ON) inhibitors (daraxonrasib, zoldonrasib) in 2/3L PDAC and NSCLC showed high response rates (up to 93% ORR) and durable disease control.

• TNG456, a CNS-penetrant PRMT5 inhibitor, is in phase 1/2 trials for glioblastoma and NSCLC, with FDA Fast Track and Orphan Drug designations for glioblastoma.

Clinical data and safety

• Vopimetostat + daraxonrasib achieved 92% ORR in 2/3L PDAC and 93% ORR in combined PDAC/NSCLC, with 100% disease control rate and encouraging durability (90% 6-month PFS in PDAC).

• Vopimetostat + zoldonrasib showed 52% ORR and 96% DCR in 2/3L PDAC, with a combined ORR of 64% for vopimetostat + RAS (ON) inhibitors in PDAC.

• Both combinations were generally well tolerated, with most adverse events being grade 1 or 2 and no new safety signals or discontinuations due to adverse events.

• Vopimetostat monotherapy showed good tolerability, low rates of dose reduction, and no grade 4-5 related events.

Market opportunity and pipeline strategy

• Approximately 60,000 patients with MTAP-deleted metastatic cancers annually in the US, with high prevalence in pancreatic, lung, and glioblastoma.

• PDAC prioritized for initial development due to high unmet need and potential for meaningful improvement over standard of care.

• Strategy includes rapid advancement of vopimetostat + daraxonrasib in 1L PDAC, expansion into other indications, and engagement with global regulators for accelerated approval pathways.

• Multiple clinical milestones anticipated by end of 2026, including phase 3 trial design, lung cancer monotherapy data, and initial TNG456 glioblastoma data.